Lifecore Biomedical Inc (LFCR)

$5.61 -0.12 (-2.09%)
Market Cap 207.71M
Revenue (ttm) 128.26M
Net Income (ttm) 12.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 9.36%
Debt to Equity Ratio 2.39
Volume 118,600
Avg Vol 239,400
Day's Range N/A - N/A
Shares Out 37.03M
Stochastic %K 3%
Beta 0.96
Analysts Sell
Price Target $8.50

Latest News on LFCR

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out

Feb 14, 2025, 10:00 AM EST - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation

Feb 13, 2025, 10:00 AM EST - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 12, 2025, 10:00 AM EST - 10 days ago

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation

Feb 11, 2025, 10:00 AM EST - 11 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Shareholders to Inquire about Securities Investigation

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 10, 2025, 10:00 AM EST - 12 days ago

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect

Feb 9, 2025, 10:00 AM EST - 13 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation

Feb 7, 2025, 10:00 AM EST - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation

Feb 6, 2025, 10:00 AM EST - 16 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 4, 2025, 10:00 AM EST - 18 days ago

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

Feb 3, 2025, 10:00 AM EST - 19 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

Feb 3, 2025, 7:00 AM EST - 19 days ago

Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation

Feb 2, 2025, 10:00 AM EST - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out

Jan 31, 2025, 10:00 AM EST - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out

Jan 30, 2025, 10:00 AM EST - 23 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out

Lifecore Biomedical Announces Special Stockholder Meeting

Jan 17, 2025, 5:24 PM EST - 5 weeks ago

Lifecore Biomedical Announces Special Stockholder Meeting

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Connect

Jan 14, 2025, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Connect

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

Jan 7, 2025, 9:00 AM EST - 6 weeks ago

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:05 PM EST - 6 weeks ago

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

Lifecore Biomedical, Inc. (LFCR) Q2 2025 Earnings Call Transcript

Jan 2, 2025, 6:19 PM EST - 7 weeks ago

Lifecore Biomedical, Inc. (LFCR) Q2 2025 Earnings Call Transcript

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

Jan 2, 2025, 4:05 PM EST - 7 weeks ago

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

Jan 2, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025

Dec 19, 2024, 4:05 PM EST - 2 months ago

Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

Dec 19, 2024, 7:00 AM EST - 2 months ago

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

Lifecore Biomedical: An Interesting CDMO Pure Play

Dec 1, 2024, 10:40 AM EST - 2 months ago

Lifecore Biomedical: An Interesting CDMO Pure Play

Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO

Nov 26, 2024, 4:05 PM EST - 3 months ago

Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO

Lifecore Biomedical Hosts Virtual Investor Day

Nov 21, 2024, 4:17 PM EST - 3 months ago

Lifecore Biomedical Hosts Virtual Investor Day

Lifecore Biomedical to Present at Stephens Annual Investment Conference

Nov 12, 2024, 4:05 PM EST - 3 months ago

Lifecore Biomedical to Present at Stephens Annual Investment Conference

Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024

Nov 7, 2024, 7:00 AM EST - 3 months ago

Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024

Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations

Nov 4, 2024, 7:00 AM EST - 3 months ago

Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations

Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options

Oct 11, 2024, 9:44 AM EDT - 4 months ago

Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options

Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript

Oct 4, 2024, 10:59 AM EDT - 5 months ago

Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

Oct 4, 2024, 7:30 AM EDT - 5 months ago

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Oct 4, 2024, 7:20 AM EDT - 5 months ago

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Oct 3, 2024, 4:05 PM EDT - 5 months ago

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

Oct 1, 2024, 7:00 AM EDT - 5 months ago

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Invited To Reach Out To The Schall Law Firm

Sep 27, 2024, 11:00 AM EDT - 5 months ago

Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Invited To Reach Out To The Schall Law Firm

FINAL DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Sep 27, 2024, 10:32 AM EDT - 5 months ago

FINAL DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

Sep 25, 2024, 4:05 PM EDT - 5 months ago

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Shareholders Are Invited To Reach Out To The Schall Law Firm

Sep 25, 2024, 11:00 AM EDT - 5 months ago

Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Shareholders Are Invited To Reach Out To The Schall Law Firm

Lifecore Biomedical, Inc. Is Being Sued For Securities Related Infractions And Impacted Stockholders Are Invited To Contact The Schall Law Firm

Sep 21, 2024, 11:00 AM EDT - 5 months ago

Lifecore Biomedical, Inc. Is Being Sued For Securities Related Infractions And Impacted Stockholders Are Invited To Contact The Schall Law Firm

The Schall Law Firm Encourages Investors To Take Part In A Case Against Lifecore Biomedical Inc For Securities Fraud

Sep 20, 2024, 11:00 AM EDT - 5 months ago

The Schall Law Firm Encourages Investors To Take Part In A Case Against Lifecore Biomedical Inc For Securities Fraud